Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome

ObjectiveTo determine the effect of treatment with vitamin D3 analogue in the parameters of glucose metabolism in obese women with polycystic ovary syndrome (PCOS).DesignObservational study.SettingObese women with PCOS in an academic research environment.Patient(s)Fifteen obese women (mean age 28 ± 1.3 years, mean body mass index 32.55 ± 0.43) with documented chronic anovulation and hyperandrogenism were recruited into the study.Intervention(s)Alphacalcidol (1-α-hydroxyvitamin D3) was administered orally 1 μg/day for 3 months. All subjects underwent a frequently sampled IV glucose tolerance test after a 10- to 12-hour overnight fast during a spontaneous bleeding episode before and after treatment with alphacalcidol.Main Outcome Measure(s)Peripheral insulin resistance and insulin effectiveness were estimated with minimal model.Result(s)The first phase of insulin secretion was significantly increased after treatment with alphacalcidol. A favorable statistically significant change also was observed in the lipid profile.Conclusion(s)Treatment with the vitamin D3 analogue (alphacalcidol) could be of value in the management of PCOS.